• Value Research Rating market-capitalisation-info
    Not Applicable
  • Market Capitalisation market-capitalisation-info $119 Mln
  • Price to Earnings Ratio price-to-earning --
  • 12 Month Earnings monthly-earning $-23 Mln

Capricor Therapeutics Inc. (CAPR) Share Price

$3.91

As on 23-Feb-2024 16:00 EST

up-down-arrow $0.030.77%

  • Prev Close info

    $3.88

  • Day's Openinfo

    $3.85

  • Today's Highinfo

    $4.12

  • Today's Lowinfo

    $3.85

  • Today's Volumeinfo

    265,304

  • 52 Week rangeinfo

    $2.68 - 8.22

Please wait...

Capricor Therapeutics Inc. (CAPR) Stock Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Capricor Therapeutics (CAPR)
-20.04 -5.78 31.21 -9.07 -16.97 -1.33 -28.99
S&P BSE Sensex
1.25 2.41 10.78 22.43 13.71 15.31 13.45
S&P Small-Cap 600#
-5.82 -5.34 -13.73 -6.30 5.30 2.98 5.53
As on 23-Feb-2024  |  #As on 26-Oct-2023
2023
2022
2021
2020
2019
2018
2017
Capricor Therapeutics (CAPR)
26.68 31.74 -14.58 167.97 -68.78 -73.86 -40.60
S&P Small-Cap 600
13.89 -17.42 25.27 9.57 20.86 -9.70 11.73
S&P BSE Sensex
18.74 4.44 21.99 15.75 14.38 5.87 27.91

Valuation Score

Stock
Peer Median
Please wait...

Growth & Efficiency

Stock
Peer Median
Please wait...

Solvency

Is there a threat to this company's solvency in the future?

Financial Manipulation

Can creative accounting be detected through the financial numbers?

Capricor Therapeutics Inc. (CAPR) Peer Comparison

search
search
search
search
    Please wait...

    Valuation Chart of Capricor Therapeutics Inc. (CAPR)

      Please wait...
        Please wait...

        Financials

        Please wait...
        Please wait...
        Please wait...

        Shareholding Pattern

        Other details of Capricor Therapeutics Inc. (CAPR)

        Executive Chairman of the Board

        Dr. Frank Isaac Litvack FACC, M.D.

        Co-Founder, President, CEO & Director

        Dr. Linda Marbán Ph.D.

        Headquarters

        San Diego, CA

        FAQs for Capricor Therapeutics Inc. (CAPR)

        The total asset value of Capricor Therapeutics Inc. (CAPR) stood at $ 70 Mln as on 30-Sep-23

        The share price of Capricor Therapeutics Inc. (CAPR) is $3.91 (NASDAQ) as of 23-Feb-2024 16:00 EST. Capricor Therapeutics Inc. (CAPR) has given a return of -16.97% in the last 3 years.

        Capricor Therapeutics Inc. (CAPR) has a market capitalisation of $ 119 Mln as on 22-Feb-2024. As per Value Research classification, it is a Small Cap company.

        The P/B ratio of Capricor Therapeutics Inc. (CAPR) is 7.73 times as on 22-Feb-2024, a 1.82% premium to its peers’ median range of 2.74 times.

        Since, TTM earnings of Capricor Therapeutics Inc. (CAPR) is negative, P/E ratio is not available.

        Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
        Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
        Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
        Step 4. Search for the Capricor Therapeutics Inc. (CAPR) and enter the required number of quantities and click on buy to purchase the shares of Capricor Therapeutics Inc. (CAPR).

        Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD). It also focused on developing StealthX, an engineered exosome platform technology which generated two vaccine candidates, such as STX-S and STX-N, induced an immune response against two SARS-CoV-2 proteins, spike, and nucleocapsid, as well as developing vaccines and therapeutics for infectious and monogenic diseases, and other potential indications. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California. Address: 10865 Road to the Cure, San Diego, CA, United States, 92121

        The CEO & director of Dr. Frank Isaac Litvack FACC, M.D.. is Capricor Therapeutics Inc. (CAPR), and CFO & Sr. VP is Dr. Linda Marbán Ph.D..

        The promoters of Capricor Therapeutics Inc. (CAPR) have pledged 0% of the total equity as on Sep-23.

        Capricor Therapeutics Inc. (CAPR) Ratios
        Return on equity(%)
        --
        Return on capital employed(%)
        --
        Debt-to-equity ratio
        0
        Dividend yield(%)
        0

        No, TTM profit after tax of Capricor Therapeutics Inc. (CAPR) was $-23 Mln.

        Edit peer-selector-edit
        Please wait...
        Please wait...

        Key Facts

        • Market cap market-cap-information $118.86 Mln
        • Revenue (TTM)revenue-information $14.05 Mln
        • Earnings (TTM) earning-information $-22.86 Mln
        • Cash date-information $28.52 Mln
        • Total Debt info $2.41 Mln
        • Insider's Holding 9.32%
        • Liquidity liquidity High
        • 52 Week range week-range $2.68 - 8.22
        • Shares outstanding share-outstanding 30,792,900
        • 10 Years Aggregate:

          CFO: $-103.43 Mln

          EBITDA: $-136.26 Mln

          Net Profit: $-149.17 Mln

        About The Company

        • IPO Date 13-Feb-2007
        • Executive Chairman of the Board Dr. Frank Isaac Litvack FACC, M.D.
        • Co-Founder, President, CEO & Director Dr. Linda Marbán Ph.D.
        • Listing key-listing NASDAQ: CAPR
        • Country United States
        • Headquarters headquarters San Diego, CA
        • Website website https://www.capricor.com
        • Business

          Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs....  Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD). It also focused on developing StealthX, an engineered exosome platform technology which generated two vaccine candidates, such as STX-S and STX-N, induced an immune response against two SARS-CoV-2 proteins, spike, and nucleocapsid, as well as developing vaccines and therapeutics for infectious and monogenic diseases, and other potential indications. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California. Address: 10865 Road to the Cure, San Diego, CA, United States, 92121  Read more

        share-fund-plan-icon